ArticleBMC pharmacology & toxicology2024

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system.

Dehua Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.